Gilead Sciences Net Profit Margin 2006-2021 | GILD

Current and historical net profit margin for Gilead Sciences (GILD) from 2006 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue. Gilead Sciences net profit margin for the three months ending September 30, 2021 was .
Gilead Sciences Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2021-09-30 $27.48B $7.39B 26.90%
2021-06-30 $26.64B $5.16B 19.38%
2021-03-31 $25.56B $0.30B 1.18%
2020-12-31 $24.69B $0.12B 0.50%
2020-09-30 $23.15B $1.27B 5.48%
2020-06-30 $22.17B $-0.26B -1.16%
2020-03-31 $22.72B $4.96B 21.84%
2019-12-31 $22.45B $5.39B 23.99%
2019-09-30 $22.37B $2.69B 12.04%
2019-06-30 $22.36B $5.96B 26.64%
2019-03-31 $22.32B $5.89B 26.40%
2018-12-31 $22.13B $5.46B 24.65%
2018-09-30 $22.28B $1.59B 7.12%
2018-06-30 $23.20B $2.21B 9.52%
2018-03-31 $24.69B $3.46B 14.03%
2017-12-31 $26.11B $4.63B 17.73%
2017-09-30 $27.48B $11.60B 42.22%
2017-06-30 $28.47B $12.21B 42.90%
2017-03-31 $29.10B $12.64B 43.42%
2016-12-31 $30.39B $13.50B 44.43%
2016-09-30 $31.58B $15.08B 47.75%
2016-06-30 $32.37B $16.35B 50.50%
2016-03-31 $32.84B $17.34B 52.81%
2015-12-31 $32.64B $18.11B 55.48%
2015-09-30 $31.45B $16.91B 53.78%
2015-06-30 $29.19B $15.04B 51.53%
2015-03-31 $27.49B $14.21B 51.69%
2014-12-31 $24.89B $12.10B 48.62%
2014-09-30 $20.70B $9.41B 45.45%
2014-06-30 $17.44B $7.46B 42.81%
2014-03-31 $13.67B $4.58B 33.51%
2013-12-31 $11.20B $3.08B 27.46%
2013-09-30 $10.67B $3.05B 28.56%
2013-06-30 $10.31B $2.93B 28.45%
2013-03-31 $9.95B $2.87B 28.87%
2012-12-31 $9.70B $2.59B 26.73%
2012-09-30 $9.31B $2.50B 26.79%
2012-06-30 $9.01B $2.56B 28.42%
2012-03-31 $8.74B $2.59B 29.68%
2011-12-31 $8.39B $2.80B 33.43%
2011-09-30 $8.18B $2.77B 33.81%
2011-06-30 $8.00B $2.73B 34.14%
2011-03-31 $7.79B $2.70B 34.62%
2010-12-31 $7.95B $2.90B 36.49%
2010-09-30 $7.98B $3.07B 38.51%
2010-06-30 $7.85B $3.04B 38.77%
2010-03-31 $7.57B $2.90B 38.34%
2009-12-31 $7.01B $2.64B 37.59%
2009-09-30 $6.41B $2.39B 37.36%
2009-06-30 $5.98B $2.22B 37.08%
2009-03-31 $5.61B $2.08B 37.10%
2008-12-31 $5.34B $1.98B 37.09%
2008-09-30 $5.00B $1.79B 35.79%
2008-06-30 $4.69B $1.69B 36.08%
2008-03-31 $4.46B $1.67B 37.33%
2007-12-31 $4.23B $1.58B 37.45%
2007-09-30 $4.03B $-0.45B -11.23%
2007-06-30 $3.72B $-0.90B -24.25%
2007-03-31 $3.36B $-1.05B -31.12%
2006-12-31 $3.03B $-1.19B -39.33%
2006-09-30 $2.74B $0.76B 27.70%
2006-06-30 $2.48B $0.99B 39.88%
2006-03-31 $2.29B $0.92B 40.17%
2005-12-31 $2.03B $0.81B 40.16%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $88.146B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09